Supernus [SUPN] vs Alkermes plc [ALKS] Detailed Stock Comparison

Supernus Pharmaceuticals Inc.

NASDAQ
Loading...

Alkermes plc

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Supernus Pharmaceuticals Inc. wins in 6 metrics, Alkermes plc wins in 14 metrics, with 0 ties. Alkermes plc appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Supernus Pharmaceuticals Inc. Alkermes plc Better
P/E Ratio (TTM) 40.66 23.71 Alkermes plc
Price-to-Book Ratio 2.66 3.09 Supernus Pharmaceuticals Inc.
Debt-to-Equity Ratio 3.86 3.85 Alkermes plc
PEG Ratio -0.33 -0.36 Supernus Pharmaceuticals Inc.
EV/EBITDA 22.87 18.26 Alkermes plc
Profit Margin (TTM) -5.36% 16.37% Alkermes plc
Operating Margin (TTM) 5.57% 15.11% Alkermes plc
EBITDA Margin (TTM) 5.57% 15.11% Alkermes plc
Return on Equity -3.68% 14.72% Alkermes plc
Return on Assets (TTM) 1.14% 6.99% Alkermes plc
Free Cash Flow (TTM) $45.99M $480.33M Alkermes plc
1-Year Return 45.68% 37.83% Supernus Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 3.93 3.83 Alkermes plc
Enterprise Value $2.68B $5.13B Alkermes plc
EV/Revenue Ratio 3.73 3.48 Alkermes plc
Gross Profit Margin (TTM) 89.13% 87.98% Supernus Pharmaceuticals Inc.
Revenue per Share (TTM) $13 $9 Supernus Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.68 $1.43 Alkermes plc
Beta (Stock Volatility) 0.73 0.39 Alkermes plc
Short % of Float 11.09% 15.90% Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc. vs Alkermes plc Stock Performance Analysis

Loading Price Chart...

SUPN
ALKS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Supernus Pharmaceuticals Inc.-0.06%-7.75%-9.38%-20.00%-0.11%-10.92%
Alkermes plc3.48%10.63%20.92%36.60%42.63%46.21%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Supernus Pharmaceuticals Inc.45.68%37.73%54.55%136.46%673.53%673.53%
Alkermes plc37.83%42.97%82.80%-6.37%138.77%104.61%

Performance & Financial Health Analysis: Supernus Pharmaceuticals Inc. vs Alkermes plc

MetricSUPNALKS
Market Information
Market Cap i$2.83B$5.55B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i492,6941,637,141
90 Day Avg. Volume i568,6012,593,004
Last Close$44.05$42.76
52 Week Range$30.83 - $59.68$25.17 - $42.87
% from 52W High-26.20%-0.26%
All-Time High$61.25 (Jun 25, 2018)$98.50 (Feb 28, 2000)
% from All-Time High-28.08%-56.59%
Growth Metrics
Quarterly Revenue Growth0.22%-0.11%
Quarterly Earnings Growth0.21%-0.66%
Financial Health
Profit Margin (TTM) i-0.05%0.16%
Operating Margin (TTM) i0.06%0.15%
Return on Equity (TTM) i-0.04%0.15%
Debt to Equity (MRQ) i3.863.85
Cash & Liquidity
Book Value per Share (MRQ)$18.48$10.99
Cash per Share (MRQ)$5.36$3.53
Operating Cash Flow (TTM) i$47.33M$520.75M
Levered Free Cash Flow (TTM) i$101.29M$-363,090,624
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Supernus Pharmaceuticals Inc. vs Alkermes plc

MetricSUPN (Apr 22, 2026)ALKS (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i40.6623.71
Forward P/E i11.6448.44
PEG Ratio i-0.33-0.36
Price to Sales (TTM) i3.933.83
Price to Book (MRQ) i2.663.09
Market Capitalization
Market Capitalization i$2.83B$5.55B
Enterprise Value i$2.68B$5.13B
Enterprise Value Metrics
Enterprise to Revenue i3.733.48
Enterprise to EBITDA i22.8718.26
Risk & Other Metrics
Beta i0.730.39
Book Value per Share (MRQ) i$18.48$10.99

Financial Statements Comparison: Supernus Pharmaceuticals Inc. vs Alkermes plc

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSUPN (2025)ALKS (2025)
Revenue/Sales i718.95M1.48B
Cost of Goods Sold i74.56M196.46M
COGS % of Revenue i10.4%13.3%
Gross Profit i644.39M1.28B
Gross Margin i89.6%86.7%
Research & Development i106.24M323.96M
Operating Income (EBIT) i-36.86M253.96M
Operating Margin i-5.1%17.2%
EBITDA i67.95M330.89M
EBITDA Margin i9.5%22.4%
Pre-Tax Income i-49.03M291.45M
Pre-Tax Income % of Revenue i-6.8%19.7%
Income Tax i-10.48M49.79M
Income Tax % of Revenue i-1.5%3.4%
Net Income (Profit) i-38.55M241.66M
Profit Margin i-5.4%16.4%

Balance Sheet & Liquidity Metrics

MetricSUPN (2025)ALKS (2025)
Cash & Equivalents i128.45M388.57M
Total Current Assets i644.18M1.93B
Total Current Assets % of Revenue i89.6%130.7%
Total Current Liabilities i338.17M543.44M
Total Current Liabilities % of Revenue i47.0%36.8%
Long-Term Debt i30.37M63.25M
Long-Term Debt % of Revenue i4.2%4.3%
Total Shareholders Equity i1.06B1.82B
Retained Earnings i517.88M-734.79M
Retained Earnings % of Revenue i72.0%-49.8%
Property, Plant & Equipment i077.21M

Cash Flow Statement Comparison

MetricSUPN (2025)ALKS (2025)
Operating Cash Flow i67.28M545.23M
Operating Cash Flow % of Revenue i9.4%36.9%
Capital Expenditures i-1.34M-39.33M
Free Cash Flow i45.99M480.33M
FCF Margin i6.4%32.5%
Debt Repayment i00
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricSUPNALKS
Shares Short i4.53M19.01M
Short Ratio i7.267.03
Short % of Float i11.09%15.90%
Shares Outstanding i57.46M165.61M
Float Shares i51.79M154.04M
% Held by Insiders i4.34%1.42%
% Held by Institutions i105.00%110.87%
% Held by Public i-9.34%-12.29%

Dividend Analysis & Yield Comparison: Supernus Pharmaceuticals Inc. vs Alkermes plc

MetricSUPNALKS
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A